Immunome, Inc. IMNM
20.31 USD +0.72 (+3.68%)
At closeNov 3, 2026, 4:28 PM EST
20.31 0.00 0.00%
After hours · Nov 3, 4:28 PM ET
19.78 Day range 20.43
14.64 52-week range 30.06
- YTD
- -5.45%
- 1 year
- +19.47%
Financial health
Altman Z-Score
32.92 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -8.8×
FY 2018 5y median -2.1× FY 2025
P/S 270×
FY 2018 5y median 15.1× FY 2025
P/B 3.0×
FY 2018 5y median 3.0× FY 2025
P/FCF -9.4×
FY 2018 5y median -8.2× FY 2025
EV/EBITDA -5.9×
FY 2018 5y median -4.1× FY 2025
EV/Sales 177×
FY 2018 5y median 8.2× FY 2025
FCF Yield -10.7%
FY 2018 5y median -12.2% FY 2025
Profitability
Gross Margin 57.4%
FY 2018 5y median 57.4% FY 2025
Operating Margin -3084.8%
FY 2018 5y median -781.4% FY 2025
Net Margin -3060.0%
FY 2018 5y median -761.9% FY 2025
ROE -33.5%
FY 2018 5y median -89.1% FY 2025
ROIC -33.5%
FY 2018 5y median -86.2% FY 2025
ROA -31.1%
FY 2018 5y median -71.9% FY 2025
Growth (YoY)
Revenue -23.2%
FY 2018 FY 2025
Operating Income 30.0%
FY 2018 FY 2025
EPS (diluted) 51.4%
FY 2018 FY 2025
Free Cash Flow -22.1%
FY 2018 FY 2025
Financial Health
Current Ratio 14.7×
FY 2018 5y median 5.8× FY 2025
Quick Ratio 14.7×
FY 2018 5y median 5.8× FY 2025
Debt / Equity 0.0×
FY 2018 5y median 0.0× FY 2025
Net Debt / EBITDA 3.1×
FY 2018 5y median 2.0× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31